MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia Y Pikman, BH Lee, T Mercher, E McDowell, BL Ebert, M Gozo, A Cuker, ... PLoS medicine 3 (7), e270, 2006 | 1765 | 2006 |
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, ... Blood 108 (10), 3472-3476, 2006 | 1329 | 2006 |
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation X Lu, R Levine, W Tong, G Wernig, Y Pikman, S Zarnegar, DG Gilliland, ... Proceedings of the National Academy of Sciences 102 (52), 18962-18967, 2005 | 375 | 2005 |
SYK is a critical regulator of FLT3 in acute myeloid leukemia A Puissant, N Fenouille, G Alexe, Y Pikman, CF Bassil, S Mehta, J Du, ... Cancer cell 25 (2), 226-242, 2014 | 153 | 2014 |
Targeting MTHFD2 in acute myeloid leukemia Y Pikman, A Puissant, G Alexe, A Furman, LM Chen, SM Frumm, L Ross, ... Journal of Experimental Medicine 213 (7), 1285-1306, 2016 | 136 | 2016 |
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model T Mercher, GD Raffel, SA Moore, MG Cornejo, D Baudry-Bluteau, ... The Journal of clinical investigation 119 (4), 852-864, 2009 | 114 | 2009 |
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia N Fenouille, CF Bassil, I Ben-Sahra, L Benajiba, G Alexe, A Ramos, ... Nature medicine 23 (3), 301-313, 2017 | 100 | 2017 |
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia Y Pikman, G Alexe, G Roti, AS Conway, A Furman, ES Lee, AE Place, ... Clinical Cancer Research 23 (4), 1012-1024, 2017 | 98 | 2017 |
Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia FF Wagner, L Benajiba, AJ Campbell, M Weïwer, JR Sacher, JP Gale, ... Science translational medicine 10 (431), eaam8460, 2018 | 85 | 2018 |
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML EB Heikamp, JA Henrich, F Perner, EM Wong, C Hatton, Y Wen, ... Blood, The Journal of the American Society of Hematology 139 (6), 894-906, 2022 | 63 | 2022 |
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray N Kawamata, S Ogawa, G Yamamoto, S Lehmann, RL Levine, Y Pikman, ... Experimental hematology 36 (11), 1471-1479, 2008 | 63 | 2008 |
Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia AE Place, Y Pikman, KE Stevenson, MH Harris, M Pauly, ML Sulis, ... Pediatric blood & cancer 65 (7), e27062, 2018 | 51 | 2018 |
Identification of prognostic factors in childhood T‐cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05‐001 and 11‐001 MA Burns, AE Place, KE Stevenson, A Gutiérrez, S Forrest, Y Pikman, ... Pediatric blood & cancer 68 (1), e28719, 2021 | 38 | 2021 |
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy Y Pikman, N Ocasio-Martinez, G Alexe, B Dimitrov, S Kitara, FF Diehl, ... Leukemia 36 (2), 348-360, 2022 | 37 | 2022 |
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma AC Wilke, C Doebele, A Zindel, KS Lee, SA Rieke, M Ceribelli, ... Blood, The Journal of the American Society of Hematology 139 (4), 538-553, 2022 | 32 | 2022 |
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor B Roux, C Vaganay, JD Vargas, G Alexe, C Benaksas, B Pardieu, ... Science translational medicine 13 (587), eabg1168, 2021 | 32 | 2021 |
Resistance mechanisms to SYK inhibition in acute myeloid leukemia A Cremer, JM Ellegast, G Alexe, ES Frank, L Ross, SH Chu, Y Pikman, ... Cancer discovery 10 (2), 214-231, 2020 | 31 | 2020 |
Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium Y Pikman, SK Tasian, ML Sulis, K Stevenson, TM Blonquist, ... Cancer discovery 11 (6), 1424-1439, 2021 | 25 | 2021 |
Targeted therapy for fusion-driven high-risk acute leukemia Y Pikman, K Stegmaier Blood, The Journal of the American Society of Hematology 132 (12), 1241-1247, 2018 | 24 | 2018 |
Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts JM Ellegast, G Alexe, A Hamze, S Lin, HJ Uckelmann, PJ Rauch, ... Cancer discovery 12 (7), 1760-1781, 2022 | 20 | 2022 |